Remedee Labs, a startup based in Paris, France, has received a European approval for its device-based approach to treating ...

After a six-month beta testing period, the European Clinical Trials Information Network is rolling out its patient ...

Meanwhile, the acquisition of AntlerA, which Roche called a leader in Wnt signaling, gives the pharma ownership of a library ...

Rivus already announced in August that the trial hit its key endpoint, but today fleshed out that win with some figures.

Bristol Myers Squibb is paying Prime Medicine $110 million upfront to develop reagents for ex vivo T-cell therapies. Prime, ...

A large trial of people with earlier stages of prostate cancer compared two types of external radiation treatments ...

Kezar Life Sciences went all in on its autoimmune candidate zetomipzomib after a restructuring last year. | The voluntary ...

Cereno Scientific’s hypertension drug was shown to improve the risk score of 43% of patients in a phase 2 study.

Having banked $60 million from Eli Lilly in the spring, Aktis Oncology has now closed an upsized $175 million series B that ...

BridgeBio Pharma has been on the road to redemption ever since its treatment for a rare and fatal heart condition, acoramidis ...

A bipolar disorder research initiative backed by Big Tech has announced $36 million in new funding for research into the ...